Retrospective observation of subacute thyroiditis before and during the COVID-19 vaccination campaign in a single secondary endocrine centre in the Savona district, Liguria, Italy

Massimo Giusti¹,²,³* and Marilena Sidoti¹,²

Abstract

Background Clinicians should be aware that subacute thyroiditis (SAT) might be an under-reported adverse effect of COVID-19 vaccines.

Aim In records from endocrinological examinations, we reviewed the incidence of diagnoses of SAT from 2000 to 2020 and during the 2021 COVID-19 vaccination campaign.

Methods Review of electronic records from June to December in each year from 2000 to 2021.

Results From 2000 to 2020, 51 patients in our centre had SAT (0.6%). From June to December 2021, 7 females were diagnosed with SAT after vaccination. The percentage of SAT in 2021 medical files was 1.5%. SAT diagnoses significantly (P = 0.03) increased in 2021 in comparison with the 2000–2020 period. The median age of SAT patients in 2021 (51 years; IQR 35–66 years) was higher than in the 2000–2020 period (45 years, IQR 38–52 years; P = 0.05).

Conclusion To date, few cases of SAT after COVID-19 vaccinations have been described in the literature, with subclinical, normal or increased thyroid function during 1-3-month follow-up. Our findings indicate that SAT after COVID-19 vaccination occurs more frequently than in other virus-related cases and at a greater age. Our observation of a local increase in SAT during the 2021 COVID-19 vaccination campaign indicates that physicians should be aware of this infrequent side effect, which must be considered and monitored after COVID-19 vaccination.

Keywords COVID-19, Subacute thyroiditis, Outcome
### Table 1 Clinical and laboratory data collected after COVID-19 vaccination in patients with diagnosis of SAT

| Case | Age years (‡) | Vaccine type | Weeks after vaccination | Symptoms | f-T4 pmol/l | TSH mIU/l | TPOAb P/N | TRAb mIU/l | CRP mg/l | US findings | Therapy |
|------|---------------|--------------|-------------------------|----------|-------------|-----------|-----------|-----------|----------|-------------|---------|
| 1    | 35            | mRNA-1273, 2nd | 2                      | neck pain  | <0.03      | nd        | nd        | nd        | nd       | FANs        |         |
|      |               |              | 6                      | palpitation | <0.03      | P         | 0.5       | 102       | diffuse, 5 | none         |         |
|      |               |              | 14                     | none       | 10.6       | 0.11      | P         | nd        | 12       | focal, 6    | none    |
| 2    | 42            | mRNA-1273, 1st | 3                      | neck pain  | 26.1       | 0.01      | P         | nd        | nd       | diffuse, nd | FANs    |
|      |               |              | 8                      | none       | nd         | 4.46      | nd        | <0.3      | 25       | normal, 8   | none    |
| 3    | 50            | BNT162b2, 2nd | 6                      | neck pain  | 16.0       | 0.06      | nd        | nd        | nd       | none         |         |
|      |               |              | 10                     | palpitation | 20.6       | 3.03      | N         | <0.3      | 48       | normal, 12  | none    |
| 4    | 51            | ChAdOx1, 1st | 4                      | neck pain  | nd         | nd        | nd        | nd        | 10       | diffuse, 20 | none    |
|      |               |              | 9                      | weight gain | 5.8        | 10.4      | N         | <0.3      | 4        | diffuse, 5  | none    |
|      |               |              | 29                     | none       | 12.0       | 5.30      | N         | nd        | nd       | diffuse, 4  | L-T4    |
| 5    | 54            | BNT162b2, 2nd | 3                      | neck pain  | 18.5       | 0.69      | N         | nd        | diffuse, 13 | prednisone |         |
|      |               |              | 10                     | none       | 11.3       | 7.60      | nd        | nd        | 33       | normal, 5   | none    |
| 6    | 61            | mRNA-1273, 1st | 4                      | palpitation | 15.6       | <0.03     | N         | nd        | focal, 9  | B-blocker    |         |
|      |               |              | 13                     | none       | 7.9        | 0.09      | N         | 0.4       | 18       | normal, 8   | B-blocker |
| 7    | 63            | BNT162b2, 1st | 4                      | neck pain  | nd         | nd        | nd        | 44        | diffuse, 18 | prednisone |         |
|      |               |              | 12                     | weight gain | 12.4       | 2.20      | N         | 46        | focal, 10 | B-blocker    |         |

Legend: nd, not done; ‡, 1st or 2nd vaccine administration before onset of SAT; P/N, positive/negative TPOAb titer; US diffuse, focal hypoechoic pattern; (*) the number indicates thyroid volume in milliliters; FANs, non-steroidal anti-inflammatory drugs

### Background

Subacute thyroiditis (SAT) due to viral infections is an infrequent cause of thyrotoxicosis [1]. Common symptoms are neck pain and tenderness on palpation [1].

In the COVID-19 era, SAT seems to be an underestimated consequence of the disease which occurs during SARS-CoV-2 infection [2]. In 2021, some cases were also reported after the administration of COVID-19 vaccines [3]. We reviewed the incidence of SAT from 2000 to 2021 in a private secondary endocrine centre in the Savona district of Liguria (Italy), which has a population of about 280,000. Vaccination of the general population had started in February 2021 and progressively involved fragile, healthy elderly, adult and young-adult subjects. By the end of 2021, about 80% of adults in the Savona district had received at least two doses of COVID-19 vaccines.

The aim of this study was to compare the incidence of SAT in these two periods: before and during the 2021 COVID-19 vaccination campaign.

### Methods

The study was conducted in the private secondary Priamar Centre for out-patients. Electronic records of all endocrinological examinations from June to December in each year from 2000 to 2020 were searched. From 8115 medical files, 51 diagnoses of SAT were anonymously retrieved (35 females; 16 males). In the corresponding period in 2021, in 466 medical files, SAT was diagnosed in 7 women after COVID-19 vaccination. The diagnosis was made according to the following findings: neck pain and tenderness on palpation, focal or diffuse hypoechoigenicity and/or heterogeneous echostucture of the thyroid on ultrasonography (US), increased inflammatory markers [erythrocytesedimentation rate (ESR) and/or C-reactive protein (CRP)], and transient clinical signs of mild/moderate thyrotoxicosis. After the onset of illness, thyroid function tests [free-thyroxine (f-T4), thyroid stimulating hormone (TSH)] and thyroid autoimmunity [thyroperoxidase antibodies (TPOAb); TSH-receptor antibodies (TRAb)] were carried out by means of commercial assays in the laboratory of Local Health Service 2 Savonese. Analytic normal ranges are: ESR<25 mm/h, CPR<5 mg/l, f-T4 12.0–22.0 pmol/l, TSH 0.3–4.2 mIU/l, TRAb<0.7 mIU/l and TPOAb (negative according to the manufacturers). Non-parametric tests (Mann-Whitney test, Fisher’s exact test) were used. The study was approved by the Priamar Centre’s institutional board, and a waiver of informed consent was granted because the research involved no risk to patients.

### Results

From 2000 to 2020, about 0.6% of the patients evaluated in our centre had SAT, which occurred at the median age of 45 years (IQR 38–52 years) with an incidence of 1–3/year. The long-term evolution of the disease was known in 25 cases (49%) and full thyroid recovery or chronic thyroiditis/hypothyroidism was observed in 72% and 28% of cases, respectively. From June to December 2021, 7 women were diagnosed with SAT after vaccination (Table 1). The percentage of SAT in 2021 medical files was 1.5%. SAT diagnoses significantly (P=0.03) increased in 2021 in comparison with the 2000–2020 period. The median age of SAT patients in 2021 (51 years; 35–66 years) was significantly higher than in the 2000–2020 period (P=0.05). To date, the median follow-up has been 12 weeks (8–29 weeks). In 3 women, a decrease in
thyroid volume was noted. When values were available (n=5) on first examination, TSH was suppressed in 80% of patients. At the last examination, TSH was still suppressed in 2 and had increased in 2; in the remaining patient, L-T4 was still ongoing. Pain, palpitations, fatigue and sweating did not recur after discontinuation of prednisone/FANs (Table 1).

Discussion
In an old study conducted in the state of Minnesota, USA, during the period 1960–1997, the incidence of SAT was reported as 4.9 cases per 100,000/year [4]. The Pria.mar Centre performs only some of the endocrine examinations in our district, where other primary public and private centres also operate; this might explain the raw 3-fold lower number of SAT cases observed. However, in 2021, when the COVID-19 vaccination campaign was at its height, we observed a significant increase in SAT. Here, we describe SAT cases that emerged 2–6 weeks (median 4 weeks) after several types of vaccines against the SARS-CoV-2 virus. To date, several cases of SAT after COVID-19 vaccinations have been described in the literature, with sub-clinical, normal or increased thyroid function in about 29%, 53% and 12% of cases, respectively, during 1-3-month follow-up (see ref 3). Recently, Bahçeceoğlu et al. [5] reported a 9.3% incidence of SAT after SARS-Cov-2 vaccination between March 2020 and July 2021, and compared this percentage with that recorded from March 2018 to July 2019. The authors did not observe a significant increase in the total number of SAT cases during the pandemic [5]. However, there are several differences between their study and ours, both in the setting (length of the reference period, inclusion in the Turkish study of both patients with SAT due to COVID-19 disease and those with SAT due to SARS-CoV-2 vaccination, secondary vs. tertiary care) and in the population analysed, which might display different HLA-based genetic susceptibility, as recently reported [6]. These differences make it difficult to compare the two studies.

SAT affects women almost 4 to 5 times as often as men and typically occurs between 25 and 35 years of age (1), although higher ages on SAT presentation have been reported [7, 8]. SAT after SARS-CoV-2 vaccines seems preferentially to involve women [3], and indeed, all 7 cases observed by us in 2021 involved women [3]. It is well known that the incidence of SAT decreases with increasing age [1]; however, we observed an increase in the age of SAT patients after 2021 vaccination in comparison with cases diagnosed in the period 2000–2020. We can speculate that this adverse event increases in parallel with the higher risk of severe COVID-19 disease complications in middle-aged and elderly subjects than in young adults. Autoimmunity is not significant in SAT [1] and TPOAb positive titres were found in only 2 of our patients in 2021. Like other viral infections [1], SARS-CoV-2 is a cause of SAT [2], and SARS-CoV-2 viral proteins have recently been detected in the thyroid tissue together with histopathological characteristics of SAT [9]. SAT after COVID-19 vaccination seems to be due to some structural similarities between follicular thyroid cells and SARS-CoV-2 antigens. In addition, the adjuvants used to induce a more substantial and sustained humoral and cellular immune response can trigger adverse immune reactions in predisposed individuals, causing autoimmune/inflammatory syndrome [10].

In conclusion, our observation of a local increase in SAT during the 2021 COVID-19 vaccination campaign indicates that physicians should be aware of this infrequent side effect, which must be considered and monitored after COVID-19 vaccination.

List of abbreviations
SAT Subacute thyroiditis.
COVID-19 Coronavirus disease.
IQR interquartile range.
SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2.
US Ultrasonography.
CRP C-reactive protein.
TSH Thyroid stimulating hormone.
FT4 Free-thyroxine.
TPOAb Thyroperoxidase antibodies.
TRAb TSH-receptor antibodies.

Acknowledgements
We thank Bernard Patrick for revising the language of the paper.

Author contributions
MG and MM contributed to the development of this research. MG was responsible for data collection and analysis. Both MG and MM wrote and approved the final version of the manuscript.

Funding source
No funding was received.

Data Availability
The datasets used and/or analysed in the present study are available from the corresponding author on reasonable request.

Declarations
Consent for publication
Not applicable.

Ethical approval
All procedures were carried out in accordance with the ethical standards of the institution and with the 1975 Helsinki Declaration, as revised in 2008. Informed consent was obtained from all women.

Disclosure
No competing financial interests exist.

Received: 20 May 2022 / Accepted: 28 September 2022
Published online: 02 November 2022
References
1. Tabassom A, Chippa V, Edens MA. De Quervain Thyroiditis. StatPearls. Treasure Island (FL): StatPearls Publishing; October 1, 2021.
2. Chen W, Tian Y, Li Z, Zhu J, Wei T, Lei J. Potential Interaction Between SARS-CoV-2 and Thyroid: A Review. Endocrinology. 2021;162(3):bqab004. doi:https://doi.org/10.1210/endoct/bqab004.
3. Jafarzadeh A, Nemati M, Jafarzadeh S, Nozari P, Mortazavi SMJ. Thyroid dysfunction following vaccination with COVID-19 vaccines: a basic review of the preliminary evidence. J Endocrinol Invest. 2022;45(3):1835–63. doi:https://doi.org/10.1007/s40618-022-01786-7.
4. Fatourechi V, Aniszewski JP, Fatourechi GZ, Atkinson EJ, Jacobsen SJ. Clinical features and outcome of subacute thyroiditis in an incidence cohort: Olmsted County, Minnesota, study. J Clin Endocrinol Metab. 2003;88(5):2100–5. doi:https://doi.org/10.1210/jc.2002-021799.
5. Bahçecioğlu AB, Karahan ZC, Aydoğan BI, Kalkan IA, Azap A, Erdoğan MF. Subacute thyroiditis during the COVID-19 pandemic: a prospective study. J Endocrinol Invest. 2022;45(4):865–74. doi:https://doi.org/10.1007/s40618-021-01718-x.
6. Şendur SN, Özmen F, Oğuz SH, İremli BG, Malkan ÜY, Gürlek A, et al. Association of human leukocyte antigen genotypes with severe acute respiratory Syndrome Coronavirus 2 vaccine-induced subacute thyroiditis. Thyroid. 2022;32(6):640–7. doi:https://doi.org/10.1089/thy.2022.0010.
7. Gorges J, Ulrich J, Keck C, Müller-Wieland D, Diederich S, Janssen OE. Long-term Outcome of Subacute Thyroiditis. Exp Clin Endocrinol Diabetes. 2020;128(11):703–8. doi:https://doi.org/10.1055/a-0998-8035.
8. Zornitzki T, Mildiner S, Schiller T, Kirzhner A, Ostrovsky V, Knebler H. Subacute thyroiditis - Still a diagnostic challenge: data from an observational Study. Int J Environ Res Public Health. 2022;19(15):9388. doi:https://doi.org/10.3390/ijerph19159388.
9. Jakovac H, Ferenčić A, Stemberger C, Mohar Vitezić B, Cuculić D. Detection of Sars-Cov-2 antigens in thyroid gland showing histopathological features of subacute thyroiditis. Eur Thyroid J. 2022;11(2):e220005. doi:https://doi.org/10.1530/EJ-T22-0005.
10. Giusti M, Maio A. Acute thyroid swelling with severe hypothyroid myxedema after COVID-19 vaccination. Clin Case Rep. 2021;9(12):e05217. doi:https://doi.org/10.1002/ccr3.5217.

Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.